• Abela, D., Ritchie, H., Ababneh, D., Gavin, C., Nilsson, M., Khan, M., Carlsson, K., Webster, W. The effect of drugs with ion channel-blocking activity on the early embryonic rat heart. Birth Defects Research. Part B, Developmental and Reproductive Toxicology. 2010; 89:429-440.
  • Nilsson, M., Danielsson, C., Skold, A., Johansson, A., Blomgren, B., Wilson, J., Khan, K., Bengtsson, E., Kultima, K., Webster, W., Danielsson, B. Improved methodology for identifying the teratogenic potential in early drug development of hERG channel blocking drugs. Reproductive Toxicology. 2010; 29:156-163.


  • Oakes, D., Ritchie, H., Woodman, P., Narup, E., Moscova, M., Picker, K., Webster, W. Genotoxicity studies of a desealant solvent mixture, SR-51. Toxicology and Industrial Health. 2009; 25:5-13.


  • Jones, K., Webster, W., Vaux, K., Benirschke, K. Acardiac fetus: evidence in support of a vascular/hypoxia pathogenesis for isolated oral clefting. Birth defects research. Part A, Clinical and molecular teratology. 2008; 82:597-600.


  • Webster, W., Abela, D. The effect of hypoxia in development. Birth defects research. Part C, Embryo today : reviews. 2007; 81:215-28.
  • Karlsson, M., Danielsson, B., Nilsson, M., Danielsson, C., Webster, W. New Proposals for Testing Drugs with IKr-Blocking Activity to Determine Their Teratogenic Potential. Current pharmaceutical design. 2007; 13:2979-2988.


  • Webster, W., Howe, A., Abela, D., Oakes, D. The relationship between cleft lip, maxillary hypoplasia, hypoxia and phenytoin. Current pharmaceutical design. 2006; 12:1431-1448.